Quality investing is a discipline that prioritizes durable profitability, strong capital allocation, and consistent growth over the hunt for cheap valuations. The Caviar Cruise screen operationalizes that philosophy by filtering for companies that can grow revenue and operating profit at a healthy clip while generating high returns on invested capital and maintaining conservative balance sheets. UNITED THERAPEUTICS CORP (NASDAQ:UTHR) is one of the names that currently passes all the screen's core tests.
How United Therapeutics scores on the quality screen
The Caviar Cruise screen starts with a base set of quantitative hurdles, then adds a few stricter requirements for investors who want an extra layer of confidence. United Therapeutics clears all of them, and the numbers are worth breaking down:
- Revenue growth (5Y CAGR): 14.07% versus the screen's 5% minimum. This shows solid expansion in the company's top line, an important sign that its commercial portfolio is finding traction.
- EBIT growth (5Y CAGR): 20.65% versus the 5% threshold. More importantly, this is comfortably above revenue growth; the gap indicates improving operating efficiency and potential pricing power.
- Return on invested capital, excluding cash, goodwill, and intangibles: 28.45% versus the 15% target. A ROIC at this level suggests management allocates capital effectively, a core requirement for buy-and-hold investors.
- Debt / free cash flow: 0.0 versus the upper limit of 5. United Therapeutics carries no outstanding debt, meaning its operations are self-funded and balance-sheet risk is low.
- Profit quality (5-year average): 87.1% versus the 75% hurdle. This shows that the large majority of reported net income has historically translated into actual free cash flow, a sign of conservative accounting and a mature business model.
Why these criteria matter for the strategy
Quality investing is built on the idea that a great company should be able to grow without relying on excessive leverage or questionable accounting. The screen's emphasis on EBIT growth outpacing revenue growth is particularly telling. United Therapeutics has achieved that, which suggests the company is benefiting from operating leverage rather than simply buying growth. Similarly, a debt-to-free-cash-flow ratio of zero means the company does not need to divert cash to creditors, leaving more room to reinvest in research, commercialization, or share repurchases.
The high ROIC figure is arguably the most important signal. A return of over 28% on core invested capital is well above the cost of capital and indicates that every dollar reinvested into the business is being put to work effectively. For a quality investor, that is the hallmark of a durable competitive advantage.
Broader fundamental picture
The overall fundamental assessment supports the screen's findings. United Therapeutics receives a 7 out of 10 fundamental rating, with standout scores in profitability and health. The company outperforms more than 95% of its biotechnology peers on return on assets, return on equity, and return on invested capital. Its operating margin of 44.49% and profit margin of 41.56% rank among the best in the industry, while the balance sheet shows no debt, a current ratio of 5.73, and an Altman-Z score of 19.77.
Growth metrics are solid as well. Earnings per share have compounded at 19.23% annually over the past five years, and analysts expect forward EPS growth of roughly 13.54% per year. On valuation, the trailing P/E of 18.93 is below the industry average and the broader S&P 500, suggesting investors are not paying an extreme premium for the quality characteristics. Those who want to review the complete breakdown can access the full fundamental analysis report.
Risks and limitations
No screen can eliminate the need for judgment. United Therapeutics does not pay a dividend, which may be a drawback for income-oriented investors. The most recent year saw revenue growth of only 2.49%, a deceleration from the five-year average, though forward projections remain solid. As with any biotech company, a meaningful portion of the thesis depends on continued commercial success for its pulmonary arterial hypertension and PH-ILD products, along with regulatory and competitive developments. Quality investors should still evaluate the qualitative side of the story, including the durability of the company's market position and the strength of its pipeline.
Cross-checks from other quality screens
United Therapeutics is not only a Caviar Cruise qualifier; it also shows up in other independently built quality screens, adding another layer of confirmation. The High ROIC screen singles out UTHR for its strong return on invested capital and efficient capital allocation, while the Quality At A Fair Price screen reinforces the same story by highlighting its high margins, cash conversion, and disciplined balance sheet. Together, these screens corroborate the article's central thesis from different angles.
Finding more companies that fit the approach
The Caviar Cruise methodology is designed to surface businesses that are built for the long run, not just for the next earnings cycle. For investors who want to apply this quality-focused framework more broadly, the Caviar Cruise stock screen offers a practical way to find other companies that pass the same demanding tests. It brings together growth, profitability, and balance sheet discipline in a single filter, making it easier to build a watchlist of potential buy-and-hold candidates.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »
View the Zacks #1 Rank List
United Therapeutics (NASDAQ:UTHR) Stands Out as a Quality Stock with Durable Profitability and Strong Returns
Quality investing is a discipline that prioritizes durable profitability, strong capital allocation, and consistent growth over the hunt for cheap valuations. The Caviar Cruise screen operationalizes that philosophy by filtering for companies that can grow revenue and operating profit at a healthy clip while generating high returns on invested capital and maintaining conservative balance sheets. UNITED THERAPEUTICS CORP (NASDAQ:UTHR) is one of the names that currently passes all the screen's core tests.
How United Therapeutics scores on the quality screen
The Caviar Cruise screen starts with a base set of quantitative hurdles, then adds a few stricter requirements for investors who want an extra layer of confidence. United Therapeutics clears all of them, and the numbers are worth breaking down:
Why these criteria matter for the strategy
Quality investing is built on the idea that a great company should be able to grow without relying on excessive leverage or questionable accounting. The screen's emphasis on EBIT growth outpacing revenue growth is particularly telling. United Therapeutics has achieved that, which suggests the company is benefiting from operating leverage rather than simply buying growth. Similarly, a debt-to-free-cash-flow ratio of zero means the company does not need to divert cash to creditors, leaving more room to reinvest in research, commercialization, or share repurchases.
The high ROIC figure is arguably the most important signal. A return of over 28% on core invested capital is well above the cost of capital and indicates that every dollar reinvested into the business is being put to work effectively. For a quality investor, that is the hallmark of a durable competitive advantage.
Broader fundamental picture
The overall fundamental assessment supports the screen's findings. United Therapeutics receives a 7 out of 10 fundamental rating, with standout scores in profitability and health. The company outperforms more than 95% of its biotechnology peers on return on assets, return on equity, and return on invested capital. Its operating margin of 44.49% and profit margin of 41.56% rank among the best in the industry, while the balance sheet shows no debt, a current ratio of 5.73, and an Altman-Z score of 19.77.
Growth metrics are solid as well. Earnings per share have compounded at 19.23% annually over the past five years, and analysts expect forward EPS growth of roughly 13.54% per year. On valuation, the trailing P/E of 18.93 is below the industry average and the broader S&P 500, suggesting investors are not paying an extreme premium for the quality characteristics. Those who want to review the complete breakdown can access the full fundamental analysis report.
Risks and limitations
No screen can eliminate the need for judgment. United Therapeutics does not pay a dividend, which may be a drawback for income-oriented investors. The most recent year saw revenue growth of only 2.49%, a deceleration from the five-year average, though forward projections remain solid. As with any biotech company, a meaningful portion of the thesis depends on continued commercial success for its pulmonary arterial hypertension and PH-ILD products, along with regulatory and competitive developments. Quality investors should still evaluate the qualitative side of the story, including the durability of the company's market position and the strength of its pipeline.
Cross-checks from other quality screens
United Therapeutics is not only a Caviar Cruise qualifier; it also shows up in other independently built quality screens, adding another layer of confirmation. The High ROIC screen singles out UTHR for its strong return on invested capital and efficient capital allocation, while the Quality At A Fair Price screen reinforces the same story by highlighting its high margins, cash conversion, and disciplined balance sheet. Together, these screens corroborate the article's central thesis from different angles.
Finding more companies that fit the approach
The Caviar Cruise methodology is designed to surface businesses that are built for the long run, not just for the next earnings cycle. For investors who want to apply this quality-focused framework more broadly, the Caviar Cruise stock screen offers a practical way to find other companies that pass the same demanding tests. It brings together growth, profitability, and balance sheet discipline in a single filter, making it easier to build a watchlist of potential buy-and-hold candidates.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »